Cabot Corporation Board Declares Dividend

On November 10, 2022, Cabot Corporation (NYSE: CBT) announced a quarterly dividend of $0.37 per share.

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

dividends

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/10/2022 - 05:00 PM

BOSTON--(BUSINESS WIRE)-- On Thursday, November 10, 2022, the Board of Directors of Cabot Corporation (NYSE:CBT) declared a quarterly dividend of $0.37 per share on all outstanding shares of the Corporation’s common stock. The dividend is payable on December 9, 2022, to stockholders of record at the close of business on November 25, 2022.

ABOUT CABOT CORPORATION

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company is a leading provider of carbon black, specialty carbons, engineered elastomer composites, inkjet colorants, masterbatches and conductive compounds, fumed silica and aerogel. For more information on Cabot, please visit the company’s website at cabotcorp.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in the press release regarding Cabot's business that are not historical facts are forward looking statements that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006120/en/

Steve Delahunt
Investor Relations
(617) 342-6255

Source: Cabot Corporation

Keep reading

More on CBT

All CBT news

Trending in the feed

CRBU

Caribou Biosciences to Evaluate Strategic Alternatives Open the live feed